Travere Therapeutics, Inc. (TVTX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Travere Therapeutics, Inc. (TVTX) closed at USD 53.27 on 2026-10-14, a change of +78.7 % over the past year, with a market capitalization of USD 4.91B.

Travere Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Travere Therapeutics, Inc. key figures

Previous close

USD 53.27 (2026-10-14)

1-year change

+78.7 %

Market cap

USD 4.91B

Enterprise value

USD 5.1B

P/E ratio (trailing)

-71.34

P/E ratio (forward)

9.36

EPS (trailing)

-0.74

EPS (forward)

5.64

PEG ratio

n/a

Price to book

203.04

Revenue growth

48.2 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

8.16

Employees

497

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Travere Therapeutics, Inc.

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase, a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. Travere Therapeutics, Inc. was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. The company is headquartered in San Diego, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Travere Therapeutics, Inc. and compare it with other stocks.